TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07858123: A 52-Week, Randomised, Double-Blind, Double-Dummy, Multinational, Multicenter, Active-Controlled, 2-Arm Parallel Group Study Comparing CHF5993 100/6/12.5 μg pMDI (Fixed Combination of Extrafine Beclomethasone Dipropionat

Sponsor: Chiesi Farmaceutici S.p.A. · Phase: PHASE3 · Area: IMMUNOLOGY · Target Enrollment: 700 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$4,360,110

Rescue Site Savings

+$2,890,410

Unlock Full NCT07858123 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07858123 Rescue Dossier →